Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC)

Annals of Oncology : Official Journal of the European Society for Medical Oncology
R PirkerH Huber

Abstract

Paclitaxel (Taxol) as single agent has shown promising activity in advanced non-small-cell lung cancer (NSCLC). Because paclitaxel lends itself to combination with other anticancer drugs, we have determined the efficacy of paclitaxel combined with cisplatin in patients with advanced NSCLC in a phase II trial. Twenty patients with NSCLC stage IIIB or IV were treated with paclitaxel (175 mg/m2) as a 3-hour infusion after standard premedication on day 1 and cisplatin (50 mg/m2 daily) on days 1 and 2. Treatment was repeated every 3 weeks. All 20 patients were evaluable for response and toxic effects. Partial responses were seen in 7 (35%) patients and no change in 9 (45%) patients. Major side effects included leukopenia, anemia, alopecia and dose-limiting neurotoxicity. Paclitaxel/cisplatin has shown good antitumor activity in patients with advanced NSCLC and should be further evaluated in this disease. Because neurotoxicity has been dose-limiting, methods for its prevention or early detection should further enhance the clinical value of this combination chemotherapy.

Citations

May 15, 1998·Current Problems in Cancer·C J Sweeney, A B Sandler
Aug 30, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·D Ferrigno, G Buccheri
Mar 14, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Alessandro MasottiGiancarlo Morandini
Oct 9, 2002·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Chih-Hung ChenThomas C Y Tsao
Oct 8, 1999·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·B JeremicG Radosavljevic-Asic
Feb 19, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G KrajnikR Pirker
Apr 20, 2001·Critical Reviews in Oncology/hematology·A Calderoni, T Cerny
Oct 8, 1999·Journal of the National Cancer Institute·J E Groopman, L M Itri
Dec 11, 2002·Expert Opinion on Pharmacotherapy·Sakkaraiappan Ramalingam, Chandra P Belani
Sep 22, 2020·Expert Opinion on Drug Delivery·Archana UpadhyaAmbikanandan Misra
Jul 5, 2005·Expert Opinion on Investigational Drugs·M Ranson, N Thatcher
May 7, 2005·Canadian Journal of Physiology and Pharmacology·Yaw L SiowKarmin O
Oct 3, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·U GatzemeierG Gallant
Jan 28, 2021·International Journal of Molecular Sciences·Shira EngelbergYoav D Livney

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.